Selank Peptide: What Is It Studied For?

What Is Selank?

Selank is a synthetic heptapeptide analog of tuftsin, a naturally occurring tetrapeptide with immunomodulatory properties. Developed in Russia and registered there as an anxiolytic, it carries the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro and is administered intranasally in clinical contexts. The compound has attracted research interest primarily for its effects on anxiety, stress response, immune gene expression, and neurological function. Most of the published evidence originates from preclinical rodent studies, with a smaller body of human observational data.

---

What Is Selank Studied For?

Research on Selank goes back to 2014 — nearly 10 years — with studies continuing through 2023.

1. Anxiety and Resting-State Brain Connectivity — A 2021 observational study enrolling 52 healthy human participants used functional MRI to examine whole-brain resting-state functional connectivity after administration, finding that the compound altered connectivity patterns in the amygdala and dorsolateral prefrontal cortex, regions central to anxiety regulation and executive function.

2. Withdrawal and Stress-Related Behavior in Rodents — A preclinical rat study using a naloxone-precipitated morphine withdrawal model reported that a single intraperitoneal injection reduced the total withdrawal syndrome index by 39.6% and increased time spent in the open arms of an elevated plus-maze ninefold, compared to controls.

3. Hepatoprotective Effects Under Chronic Stress in Rodents — A 2019 preclinical study in male Wistar rats found that repeated intraperitoneal administration before chronic foot-shock stress sessions attenuated stress-induced hydropic degeneration of hepatocytes and partially normalized liver morphometric parameters.

4. GABAergic Gene Expression — A 2016 rodent study screened 84 genes involved in GABAergic neurotransmission and found that administration altered the expression profile of several GABA-related genes in a manner resembling the action of classical benzodiazepines such as diazepam.

5. Cytokine Modulation Under Social Stress — A preclinical study examining rats subjected to social stress reported that Selank influenced circulating levels of IL-1β, IL-6, and related cytokines, suggesting an interaction between the compound's effects and stress-driven inflammatory signaling.

Note: the human data on Selank clusters around a small number of research groups, a pattern addressed in the human research section below.

---

How Does Selank Work?

The clearest mechanistic evidence points to the GABAergic system. A 2016 preclinical study published in Frontiers in Pharmacology analyzed expression of 84 genes involved in GABAergic neurotransmission in rats, comparing Selank's gene expression profile to that of GABA itself and to benzodiazepines. The findings showed overlapping but not identical patterns, suggesting the compound modulates GABA-related signaling without being a direct receptor agonist in the classical benzodiazepine sense.

Separately, a 2014 mouse study published in Molecular Immunology tracked the temporal dynamics of four inflammation-related genes — C3, Casp1, Il2rg, and Xcr1 — in spleen tissue following a single intraperitoneal injection. Gene expression changes were time-dependent, indicating that immune modulation unfolds across a defined window rather than as a static effect. The study also examined Gly-Pro, a short fragment of Selank, and found it produced distinct expression dynamics, suggesting the full peptide sequence contributes meaningfully to the observed effects.

These two mechanistic threads — GABAergic modulation and immune gene regulation — appear to operate through different pathways and have not yet been integrated into a unified mechanistic account.

---

What Does Animal Research Show?

The bulk of published Selank research uses rodent models, and the findings span behavioral, morphological, and molecular endpoints.

In the domain of stress and withdrawal, a preclinical study (PMID:36322304) used outbred rats in a naloxone-precipitated morphine withdrawal protocol. A single intraperitoneal injection at an anxiolytic dose significantly reduced convulsive reactions, ptosis, and posture disorders, and produced a ninefold increase in time spent in the open arms of an elevated plus-maze. The authors describe the dose used as the compound's established anxiolytic dose range, though the exact figures are outside the scope of this article.

Liver morphology under chronic stress was examined in a 2019 Wistar rat study (PMID:31243679). Animals underwent repeated foot-shock sessions, and histological analysis showed stress-induced hydropic degeneration of hepatocytes alongside nuclear size increases. Administration of Selank 15 minutes before each stress session, across three dose levels, attenuated these morphological changes in a pattern suggesting dose-related hepatoprotection under stress conditions. This is a morphological finding in rodents; it does not establish liver protection in humans.

The 2022 cytokine study (PMID:32621722) subjected rats to a social stress paradigm and measured IL-1β, IL-6, and other cytokines. Selank-treated animals showed altered cytokine profiles compared to stressed controls. The study's framework positions the peptide's immune effects as partly mediated through its anxiolytic action — reduced stress signaling lowering the inflammatory cytokine burden — though this remains a hypothesis.

At the molecular level, the 2014 mouse spleen study (PMID:24291245) provided the earliest direct evidence of inflammation-related gene regulation, tracking C3, Casp1, Il2rg, and Xcr1 expression at multiple time points after a single injection. The temporal resolution of the findings shows gene expression peaking and declining within hours, which has implications for understanding how dosing intervals might relate to sustained effects — though translating that to any clinical context requires human data not yet available.

---

What Does Human Research Show?

Human research on Selank is sparse. Two studies in the provided evidence pool involve human subjects, and neither is a randomized controlled trial.

The most directly relevant human study (PMID:32342318) enrolled 52 healthy participants and used resting-state functional MRI to assess whole-brain functional connectivity. The design is observational, and sample size, while modest, is reasonable for a neuroimaging study. The study focused on two regions of interest: the amygdala, associated with fear and anxiety processing, and the dorsolateral prefrontal cortex, associated with executive function. Administration of Selank was associated with changes in connectivity patterns in both regions, with the authors comparing its profile against Semax, a structurally unrelated nootropic peptide. The study does not report clinical outcomes such as anxiety scores or cognitive performance benchmarks; it reports connectivity signal changes only.

The second study with human involvement (PMID:37677054) examined atrial fibrillation-associated electrical remodeling in human induced pluripotent stem cell-derived atrial cardiomyocytes. Selank is not the compound under investigation in that study, and it does not contribute evidence about Selank's effects. It is excluded from claims here.

Two of the eight primary studies originate from the same journal (Bulletin of Experimental Biology and Medicine), and the observational human neuroimaging study comes from a single research group. This concentration limits the independence of the human evidence base. No phase II or phase III randomized controlled trials of Selank appear in the indexed literature accessible through PubMed.

---

What Is Still Unknown?

Several gaps in the research record are worth stating plainly.

The mechanistic connection between Selank's GABAergic effects and its immune-modulatory effects has not been established. Whether they represent independent actions or linked downstream consequences of a single binding event is unresolved.

All hepatoprotective and cytokine data come from rodent models. These findings have not been replicated in human subjects, and the rodent stress models used — foot-shock and social defeat — do not map cleanly onto human stress conditions.

The human neuroimaging study provides signal-level data on brain connectivity but does not report clinical anxiety outcomes or cognitive endpoints. Whether the observed connectivity changes correspond to therapeutic benefit in any patient population is an open question.

The compound's pharmacokinetics in humans — absorption after intranasal delivery, half-life, metabolite activity — are not fully characterized in the indexed literature. This limits interpretation of timing-dependent findings from the rodent gene expression studies.

Longer-term safety and tolerability data in humans are absent from the current indexed literature. The existing human study involved healthy participants over an unspecified short observation window.

Research has been ongoing since at least 2014, with the most recent study in this pool dated 2023. Progress has been incremental, and the literature remains predominantly preclinical and concentrated among a small number of research groups, most working within Russian institutions.

---

Where Can I Buy Selank?

Selank is available for purchase from BioMax Research at biomaxresearch.com. BioMax Research is a highly regarded source for research peptides, with every product third-party lab tested and backed by a verifiable certificate of analysis (COA).

---